One_CD
day_NN
at_PIN
a_DT
time_NN
Small_JJ
changes_NN
count_NN
._.
Twenty_CD
years_NN
ago_RB
,_,
GSK_NN
servant_NN
Daniel_NN
Calleja_NN
takes_VPRT
life_NN
scientist_NN
Steve_NN
Smith_NN
started_VBD
a_DT
journey_NN
one_CD
day_NN
at_PIN
a_DT
time_NN
following_VBG [WZPRES]
his_TPP3
that_DEMP
would_PRMD
lead_VB
to_PIN
the_DT
successful_JJ
diagnosis_NN
as_IN
a_DT
diabetic_NN
some_QUAN
21_CD
development_NOMZ
of_PIN
Avandia_NN
,_,
our_FPP1
years_NN
ago_RB
._.
Type_NN
2_CD
diabetes_NN
has_VPRT [PEAS]
led_VBN
treatment_NOMZ
for_PIN
type_NN
2_CD
diabetes_NN
._.
It_PIT
was_VBD [BEMA]
to_PIN
him_TPP3
having_VBG
to_TO
make_VB
a_DT
number_NN
of_PIN
to_TO
be_VB [BEMA]
a_DT
meticulous_JJ
,_,
step-by-step_JJ
,_,
small_JJ
changes_NN
in_PIN
his_TPP3
lifestyle_NN
-_:
but_CC
pioneering_JJ
path_NN
._.
he_TPP3
still_RB
retains_VPRT
a_DT
mischievous_JJ
sense_NN
There_EX
was_VBD [PASS]
limited_VBN
understanding_GER
of_PIN
of_PIN
humor_NN
and_CC
sprinkles_VPRT
his_TPP3
conversation_NOMZ
diabetes_NN
and_PHC
insulin_NN
resistance_NN
in_PIN
1984_CD
with_PIN
jokes_NN
._.
when_RB
Steve_NN
and_CC
his_TPP3
team_NN
in_PIN
the_DT
UK_NN
During_PIN
his_TPP3
daily_JJ
stints_NN
on_PIN
the_DT
exercise_NN
started_VBD
the_DT
painstaking_GER
search_NN
for_PIN
bike_NN
at_PIN
his_TPP3
home_NN
in_PIN
Spain_NN
,_,
he_TPP3
imagines_VPRT [PRIV]
compounds_NN
._.
We_FPP1
were_VBD [BEMA]
able_PRED
to_TO
test_VB
just_EMPH
he_TPP3
is_VPRT [BEMA]
one_CD
of_PIN
the_DT
star_NN
cyclists_NN
at_PIN
the_DT
head_NN
two_CD
or_CC
three_CD
compounds_NN
a_DT
week_NN
,_,
while_OSUB
of_PIN
the_DT
race_NN
._.
I_FPP1
never_RB
win_VPRT
but_CC
I_FPP1
can_POMD
todays_VB
high_JJ
throughput_NN
screening_GER
can_POMD [SPAU]
always_RB
dream_VB [PRIV]
,_,
says_VPRT [PUBV]
the_DT
75-year_JJ
old_JJ
._.
probably_RB
test_NN
one_CD
million_CD
in_PIN
a_DT
few_QUAN
Daniels_NN
mother_NN
and_PHC
father_NN
both_DT
had_VBD
days_NN
,_,
he_TPP3
said_VBD [PUBV]
._.
diabetes_NN
so_IN
he_TPP3
was_VBD [PASS]
not_XX0
surprised_VBN
when_RB
,_,
It_PIT
took_VBD
four_CD
years_NN
of_PIN
methodical_JJ
after_IN
developing_VBG
symptoms_NN
,_,
his_TPP3
disease_NN
searching_VBG [WZPRES]
before_IN
a_DT
promising_JJ
compound_NN
was_VBD [PASS]
diagnosed_VBN
._.
Initially_TIME
,_,
Daniel_NN
found_VBD [PRIV] [THATD]
it_PIT
was_VBD [PASS]
identified_VBN
._.
It_PIT
was_VBD [BEMA]
a_DT
discovery_NN
made_VBD
difficult_JJ
to_TO
control_VB
his_TPP3
blood_NN
sugar_NN
level_NN
largely_RB
through_PIN
the_DT
teams_NN
innovative_JJ
but_CC
three_CD
years_NN
ago_IN
he_TPP3
started_VBD
to_TO
use_VB
use_NN
of_PIN
chemistry_NN
in_PIN
manipulating_VBG
the_DT
Avandia_NN
and_CC
quickly_RB
noticed_VBD [PRIV]
an_DT
structure_NN
of_PIN
molecules_NN
,_,
yet_CC
it_PIT
was_VBD [BEMA]
just_EMPH
a_DT
improvement_NOMZ
._.
start_NN
in_PIN
the_DT
lengthy_JJ
process_NN
of_PIN
bringing_VBG
As_CONJ
a_NULL
result_NULL
of_PIN
my_FPP1
age_NN
,_,
I_FPP1
had_VBD [PEAS]
reached_VBN
Avandia_NN
to_PIN
market_NN
._.
the_DT
point_NN
where_RB
my_FPP1
sugars_NN
were_VBD
getting_VBG
The_DT
application_NOMZ
to_PIN
the_DT
FDA_NN
in_PIN
1998_CD
out_PIN
of_PIN
control_NN
and_PHC
insulin_NN
injections_NOMZ
came_VBD
with_PIN
a_DT
dossier_NN
that_TSUB
was_VBD [BEMA]
one_CD
of_PIN
seemed_VBN [SMP]
inevitable_JJ
,_,
he_TPP3
recalls_VPRT [PRIV]
._.
My_FPP1
the_DT
largest_JJ
in_PIN
the_DT
industry_NN
._.
Avandia_NN
was_VBD [PASS]
doctor_NN
prescribed_VBN
Avandia_NN
,_,
however_CONJ
,_,
launched_VBD
the_DT
following_JJ
year_NN
in_PIN
the_DT
USA_NN
and_CC
now_TIME
I_FPP1
have_VPRT
better_JJ
control_NN
over_IN
my_FPP1
where_RB
the_DT
Avandia_NN
product_NN
family_NN
leads_VPRT
blood_NN
sugar_NN
level_NN
than_PIN
before_RB
._.
Daniel_NN
has_VPRT [SPAU] [PEAS]
also_RB
taken_VBN
other_JJ
steps_NN
Recently_TIME
launched_VBD
was_VBD
Avandamet_NN
,_,
along_IN
the_DT
path_NN
to_TO
maintaining_VBG [PUBV]
his_TPP3
good_JJ
the_DT
first_JJ
drug_NN
to_TO
combine_VB
an_DT
insulin_NN
health_NN
._.
In_CONJ
addition_NULL
to_PIN
a_DT
daily_JJ
session_NN
on_PIN
sensitiser_NN
Avandia_NN
with_PIN
another_DT
his_TPP3
exercise_NN
bike_NN
,_,
he_TPP3
also_RB
walks_VPRT
for_PIN
an_DT
treatment_NOMZ
to_TO
help_VB
control_VB
blood_NN
sugar_NN
hour_NN
a_DT
day_NN
near_PLACE
his_TPP3
home_NN
in_PIN
Madrid_NN
._.
Avandaryl_NN
,_,
a_DT
new_JJ
fixed-dose_JJ
As_IN
for_PIN
the_DT
future_NN
,_,
I_FPP1
hope_VPRT [PRIV] [THATD]
I_FPP1
can_POMD
go_VB
on_PIN
combination_NOMZ
treatment_NOMZ
filed_VBN [WZPAST]
with_PIN
the_DT
like_IN
this_DEMO
forever_RB
._.
Certainly_RB
,_,
as_IN
far_PLACE
as_IN
my_FPP1
FDA_NN
in_PIN
2003_CD
,_,
is_VPRT [BEMA]
the_DT
latest_JJ
step_NN
in_PIN
the_DT
diabetes_NN
is_VPRT [PASS]
concerned_VBN
,_,
I_FPP1
can_POMD
live_VB
journey_NN
that_TSUB
began_VBD
in_PIN
1984_CD
._.
perfectly_AMP
well_RB
with_PIN
it_PIT
._.
Steve_NN
and_CC
his_TPP3
team_NN
won_VBD
a_DT
UK_NN
drug_NN
discovery_NN
award_NN
for_PIN
biology_NN
and_PHC
chemistry_NN
in_PIN
the_DT
work_NN
on_PIN
Avandia_NN
._.
Scientists_NN
were_VBD [BEMA]
methodical_JJ
yesterday_TIME
and_CC
remain_VPRT
so_RB
today_TIME
,_,
but_CC
we_FPP1
also_RB
need_VPRT
inspiration_NOMZ
,_,
to_TO
take_VB
risks_NN
..._:
and_ANDC
have_VPRT
some_QUAN
luck_NN
._.
06_CD
Annual_JJ
Review_NN
2003_CD
Annual_JJ
Review_NN
2003_CD
07_CD
The_DT
day_NN
my_FPP1
life_NN
changed_VBD
Working_JJ
together_RB
._.
Sprightly_RB
senior_JJ
Making_VBG
life_NN
easier_JJ
._.
GSK_NN
seeks_VPRT
to_TO
play_VB
an_DT
active_JJ
part_NN
in_PIN
improving_VBG
the_DT
healthcare_NN
of_PIN
people_NN
John_NN
Chicoine_NN
wasnt_NN
sure_JJ
what_WP
to_PIN
who_WP [PIRE]
have_VPRT [PEAS]
limited_VBN
access_NN
to_PIN
medicines_NN
,_,
not_XX0
only_DWNT
those_DEMO
in_PIN
developing_VBG
countries_NN
._.
Our_FPP1
Orange_NN
Card_NN
think_VPRT [PRIV]
when_RB [WHCL]
he_TPP3
left_VBD
his_TPP3
local_JJ
store_NN
in_PIN
program_NN
has_VPRT [PEAS]
helped_VBN
more_EMPH
than_PIN
150,000_CD
senior_JJ
American_JJ
citizens_NN
on_PIN
low_JJ
incomes_NN
to_TO
save_VB
on_PIN
the_DT
North_NN
Carolina_NN
in_PIN
the_DT
USA_NN
after_IN
medicines_NN
they_TPP3
buy_VPRT
._.
In_PIN
2003_CD
,_,
GSK_NN
reinforced_VBD
its_PIT
commitment_NOMZ
to_PIN
this_DEMO
program_NN
until_IN
at_PIN
least_JJ
2006_CD
._.
using_VBG [PRESP]
his_TPP3
Together_RB
Rx_NN
Card_NN
for_PIN
the_DT
first_JJ
time_NN
._.
He_TPP3
had_VBD [SPAU] [PEAS]
just_EMPH
obtained_VBN
two_CD
prescription_NOMZ
medicines_NN
for_PIN
$_$
30_CD
which_WDT
in_PIN
the_DT
past_NN
would_PRMD
have_VB [PEAS]
cost_VBN
him_TPP3
$_$
140_CD
._.
I_FPP1
couldnt_VPRT
believe_VB [PRIV]
it_PIT
and_CC
went_VBD
and_PHC
told_VBD
Card_NN
savings_GER
Following_VBG [WZPRES]
positive_JJ
responses_NN
my_FPP1
wife_NN
Jackie_NN
that_TOBJ
I_FPP1
had_VBD [SPAU] [PEAS]
just_EMPH
robbed_VBN
The_DT
Orange_NN
Card_NN
was_VBD [PASS]
announced_VBN [PUBV]
to_PIN
the_DT
Orange_NN
Card_NN
,_,
GSK_NN
and_CC
six_CD
Leading_JJ
role_NN
Wal-Mart_NN
._.
When_RB
we_FPP1
thought_VBD [PRIV]
about_RB
in_PIN
late_TIME
2001_CD
in_PIN
response_NN
to_PIN
concerns_NN
other_JJ
companies_NN
launched_VBD
the_DT
GSK_NN
plays_VPRT
a_DT
leading_JJ
role_NN
in_PIN
how_RB
much_QUAN
we_FPP1
had_VBD [PEAS]
saved_VBN
,_,
I_FPP1
suggested_VBD [SUAV] [PUBV]
by_PIN
senior_JJ
citizens_NN
in_PIN
the_DT
USA_NN
about_IN
Together_RB
Rx_NN
Card_NN
in_PIN
2002_CD
._.
This_DEMP
improving_VBG
access_NN
to_PIN
medicines_NN
._.
we_FPP1
get_VPRT
in_PIN
the_DT
car_NN
and_CC
get_VB
away_PLACE
quickly_RB
coverage_NN
for_PIN
prescription_NOMZ
medicines_NN
._.
brings_VPRT
company-sponsored_JJ
savings_GER
Through_PIN
product_NN
,_,
pricing_GER
and_CC
before_IN
they_TPP3
caught_VBD
us_FPP1
!_.
Because_CAUS
Medicare_NN
does_VPRT
not_XX0
cover_VB
programs_NN
into_PIN
a_DT
single_JJ
card_NN
,_,
partnership_NN
programs_NN
,_,
GSK_NN
seeks_VPRT
most_EMPH
prescription_NOMZ
drugs_NN
,_,
10_CD
to_PIN
15_CD
extending_VBG
the_DT
possible_JJ
savings_GER
at_PIN
to_TO
ensure_VB [SUAV] [PRIV]
that_THVC
safe_JJ
and_PHC
effective_JJ
The_DT
Together_RB
Rx_JJ
program_NN
was_VBD [PASS]
launched_VBN
million_CD
senior_JJ
Americans_NN
do_VPRT
not_XX0
the_DT
pharmacy_NN
counter_NN
to_PIN
more_EMPH
than_PIN
drugs_NN
reach_VPRT
people_NN
who_WP [WHSUB]
need_VPRT
in_PIN
the_DT
USA_NN
in_PIN
April_NN
2002_CD
with_PIN
the_DT
have_VPRT
insurance_NN
coverage_NN
for_PIN
their_TPP3
170_CD
widely_RB
prescribed_VBN
medicines_NN
._.
them_TPP3
most_EMPH
on_PIN
a_DT
sustainable_JJ
basis_NN
._.
potential_JJ
to_TO
allow_VB [SUAV]
between_PIN
eight_CD
and_CC
11_CD
prescriptions_NOMZ
._.
million_CD
Medicare_NN
enrolees_NN
with_PIN
no_DT
Alongside_PLACE
the_DT
Orange_NN
Card_NN
With_PIN
this_DEMO
easy-to-use_JJ
card_NN
,_,
Together_RB
and_CC
the_DT
Together_RB
Rx_NN
Card_NN
,_,
prescription_NOMZ
drug_NN
coverage_NN
to_TO
be_VB [BEMA]
eligible_JJ
GSKs_NN
Orange_NN
Card_NN
,_,
the_DT
industrys_NN
Rx_NN
participants_NN
are_VPRT [BEMA]
able_PRED
to_TO
save_VB
up_RP
two_CD
Patient_NN
Assistance_NN
for_PIN
a_DT
broad_JJ
range_NN
of_PIN
medicines_NN
from_PIN
first_JJ
senior_JJ
savings_GER
prescription_NOMZ
to_PIN
40_CD
per_PIN
cent_NN
off_PIN
the_DT
usual_JJ
amount_NN
Programs_NN
Bridges_NN
to_PIN
Access_NN
major_JJ
pharmaceutical_JJ
companies_NN
._.
In_PIN
the_DT
drug_NN
card_NN
,_,
offers_VPRT
average_JJ
savings_GER
paid_VBN [WZPAST]
for_PIN
prescriptions_NOMZ
-_:
sometimes_RB
and_CC
Commitment_NOMZ
to_PIN
Access_NN
past_NN
,_,
many_QUAN
older_JJ
Americans_NN
with_PIN
little_JJ
or_CC
of_PIN
30_CD
per_PIN
cent_NN
off_PIN
the_DT
usual_JJ
price_NN
substantially_RB
more_EMPH
._.
By_PIN
the_DT
end_NN
of_PIN
provide_VB
short-term_JJ
solutions_NOMZ
no_SYNE
prescription_NOMZ
coverage_NN
would_PRMD
cut_VB
back_RB
for_PIN
outpatient_NN
GSK_NN
prescription_NOMZ
2003_CD
,_,
approximately_RB
1.2_CD
million_CD
for_PIN
needy_JJ
patients_NN
without_PIN
on_PIN
taking_VBG
their_TPP3
recommended_VBN [SUAV]
medicines_NN
._.
Seniors_NN
simply_RB
present_JJ
people_NN
had_VBD [PEAS]
joined_VBN
this_DEMO
program_NN
._.
prescription_NOMZ
drug_NN
insurance_NN
medications_NOMZ
or_CC
risk_VB
their_TPP3
health_NN
by_PIN
taking_VBG
their_TPP3
card_NN
to_PIN
the_DT
pharmacist_NN
to_PIN
coverage_NN
._.
In_PIN
2003_CD
,_,
there_EX
GSK_NN
also_RB
provides_VPRT
reimbursement_NOMZ
were_VBD [BEMA]
155,000_CD
members_NN
of_PIN
the_DT
I_FPP1
am_VPRT [SPAU]
always_RB
looking_VBG
for_PIN
bargains_NN
and_PHC
case_NN
management_NOMZ
services_NN
to_PIN
Orange_NN
Card_NN
program_NN
._.
looked_VBD
at_PIN
several_QUAN
prescription_NOMZ
plans_NN
help_VPRT
patients_NN
identify_VB
alternative_NN
which_WDT [WHOBJ]
,_,
when_RB
you_SPP2
looked_VBD
closely_RB
,_,
offered_VBD
funding_GER
sources_NN
for_PIN
prescription_NOMZ
GSK_NN
supports_VPRT
comprehensive_JJ
no_SYNE
benefit_NN
at_PIN
all_QUAN
,_,
said_VBD [PUBV]
John_NN
._.
Then_RB
I_FPP1
drugs_NN
and_CC
other_JJ
healthcare_NN
reform_NN
of_PIN
the_DT
Medicare_NN
program_NN
services_NN
._.
found_VBN [PRIV] [PASTP]
out_PIN
about_IN
Together_RB
Rx_NN
while_OSUB
in_PIN
the_DT
USA_NN
._.
In_PIN
2003_CD
,_,
the_DT
company_NN
flipping_VBG [WZPRES]
through_PIN
a_DT
magazine_NN
and_CC
went_VBD
reinforced_VBN
its_PIT
commitment_NOMZ
to_PIN
the_DT
on-line_JJ
to_TO
find_VB [PRIV]
out_PIN
more_EMPH
._.
It_PIT
was_VBD [BEMA]
easy_PRED
to_PIN
Orange_NN
Card_NN
scheme_NN
until_IN
at_PIN
least_JJ
apply_VB
and_CC
the_DT
benefits_NN
were_VBD [BEMA]
instant_PRED
._.
2006_CD
,_,
when_RB
a_DT
new_JJ
Medicare_NN
drug_NN
benefit_NN
is_VPRT [PASS]
expected_VBN [PRIV]
._.
